Gladstone NOW: The Campaign Join Us on the Journey✕
Deepak Srivastava is selected as a Bay Area innovator
A group of entrepreneurs and visionaries who fuel business innovation were selected as the inaugural Upstart 50 by the San Francisco Business Times and the Silicon Valley Business Journal. At an event held on September 12, 2017, Deepak Srivastava, MD, was honored as an Upstart 50 Inventor.
Srivastava, director of the Gladstone Institute of Cardiovascular Disease, was selected for his innovative cardiology research on the regeneration of damaged heart tissue. A co-founder of Tenaya Therapeutics, he was also chosen for his efforts to bring his discoveries to market to fight the world’s leading cause of death—heart disease.
“My goal is to deeply understand how stem cells can be used to alleviate suffering among the millions of children and adults with heart disease worldwide,” said Srivastava.
The Upstart 50 list recognizes the most innovative startup founders, venture capitalists, creative minds, and influencers for their impact on business—not only throughout the Bay Area and Silicon Valley, but also far beyond.
The Inventor category includes people behind the companies and technologies changing the world. These leaders “have a tendency to think differently and disrupt industries,” according to the Upstart 50 project manager, Kevin Truong.
When asked what industry needs to be disrupted, Srivastava pointed to the delivery of medical care.
“This field missed the technology boom and is just now catching up,” he said. “The ability to leverage new information technologies, machine learning, and artificial intelligence to diagnose, manage, and track human disease will fundamentally change healthcare.”
Our people are our most important asset. We offer a wide array of career opportunities both in our administrative offices and in our labs.
Explore CareersSrivastava will present at the American Heart Association’s Scientific Sessions 2025 in New Orleans; the lectureship is a major recognition of excellence by the association.
News Release Cardiovascular Disease Srivastava Lab Genomics Stem Cells/iPSCsIn this video, Gladstone scientists share how they used stem cells, gene editing, and AI to identify a gene driving heart defects in Down syndrome—and how reducing its levels in mice restored normal heart development, offering hope for future treatments
Gladstone Experts Cardiovascular Disease Data Science and Biotechnology Pollard Lab Srivastava Lab AI Big Data CRISPR/Gene Editing Human Genetics Stem Cells/iPSCsAfter decades of mystery, Gladstone researchers identify a gene that can derail heart formation—and show that fixing it prevents the problem in mice.
News Release Research (Publication) Congenital Heart Disease Cardiovascular Disease Pollard Lab Srivastava Lab AI CRISPR/Gene Editing Stem Cells/iPSCs